USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Resmed R&D Germany Gmbh

USPTO PatentsView assignee record - 32 granted patents across 9 technology areas, active 2015–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).

32
Total patents granted
9
CPC technology areas
27.7
Avg claims per patent
-97%
5-year filing velocity

The verdict

Resmed holds 32 US patents across 9 technology areas, rank #9,860 of 50,000 tracked assignees.

#9,860
of 50,000 US assignees by volume
Top 43%
by Innovation Score (37.7/100)
27.7
avg claims per patent
-97%
filing velocity, last 5 yrs

Portfolio overview

ResMed R&D Germany GmbH has been granted 32 US utility patents between 2015 and 2020, placing ResMed R&D Germany GmbH at rank #9,860 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 27.7 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, ResMed R&D Germany GmbH is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 37.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 31 in the 2015–2019 window, a -97% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. ResMed R&D Germany GmbH's 27.7 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ResMed R&D Germany GmbH against peers pursuing similar technology classes.

How does ResMed compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows ResMed holds 32 patents, placing it at rank #9,860 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

ResMed's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

0246810 201520162017201820192020 1
USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
ResMed R&D Germany GmbH patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 5 15.6%
2016 8 25.0%
2017 8 25.0%
2018 6 18.8%
2019 4 12.5%
2020 1 3.1%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining

Where it ranks

Overall rank by patents

#9,860

Across all tracked assignees

Innovation Score

37.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does ResMed R&D Germany GmbH hold?
ResMed R&D Germany GmbH holds 32 US granted patents filed between 2015 and 2020, spanning 9 technology areas.
What is ResMed R&D Germany GmbH's Innovation Score?
ResMed R&D Germany GmbH has an Innovation Score of 37.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ResMed R&D Germany GmbH focus on?
ResMed R&D Germany GmbH's top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 29 patents. The company has filed patents in 9 CPC subclasses total.
Is ResMed R&D Germany GmbH's patent filing rate increasing or decreasing?
ResMed R&D Germany GmbH's recent filing velocity is -97% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for ResMed R&D Germany GmbH's patents?
ResMed R&D Germany GmbH's patents average 27.7 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the ResMed R&D Germany GmbH patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Resmed's 32 grants land it in the top 43% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Resmed ranks #9,860 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61M - see who else leads that technology area. A61M leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov